At 10 years, TF-TAVR was associated with a higher risk of all-cause mortality (HR 1.39) and MACCE (HR 1.33) compared to SAVR, but lower risk of repeat aortic intervention (SHR 0.33).
Does transfemoral TAVR compared to SAVR improve 10-year mortality and MACCE in patients with severe aortic stenosis?
At 10-year follow-up in real-world practice, early-generation TAVR was associated with higher mortality and MACCE but lower repeat aortic intervention compared to SAVR.
Absolute Event Rate: 0% vs 0%
Abstract OBJECTIVES To compare long-term clinical outcomes of patients undergoing surgical (SAVR) or transcatheter aortic valve replacement (TAVR) in the Italian clinical practice and enrolled in the multicentre OBSERVANT (Observational Study of Effectiveness of SAVR–TAVI Procedures for Severe Aortic Stenosis Treatment) Study. METHODS Propensity score matching was used to compare patients undergoing SAVR or transfemoral (TF) TAVR with similar baseline characteristics. The primary end-points were all-cause mortality and major adverse cardiac and cerebrovascular events (MACCE) at 10 years. Prespecified secondary end-points included cerebrovascular accidents, repeat aortic intervention, repeat hospitalization due to cardiac reasons and heart failure. All outcomes were adjudicated through a linkage with administrative databases. RESULTS From the entire cohort (n = 5707 SAVR and n = 1911 TAVR treated between December 2010 and June 2012), 650 matched pairs of patients were considered. At 10 years, TF-TAVR was associated with a higher risk of all-cause mortality Hazard ratio (HR) 1.39, 95% confidence interval (CI) 1.22–1.59; p 0.001 and MACCE (HR 1.33, 95% CI 1.18–1.51; p 0.001) compared to SAVR. Secondary end-points did not differ for rehospitalization for heart failure (p = 0.443) or cardiac reasons (p = 0.552), and for cerebrovascular events (p = 0.573), but TAVR had a significantly lower risk of repeat aortic intervention Sub-distributional HR (SHR), 0.33; 95% CI, 0.12–0.91; p = 0.024 at 10 years. CONCLUSIONS At 10 years, early generation TAVR had significantly higher risk of all-cause mortality and MACCE, but lower risk of repeat aortic intervention in clinical practice.
Costa et al. (Mon,) reported a other. At 10 years, TF-TAVR was associated with a higher risk of all-cause mortality (HR 1.39) and MACCE (HR 1.33) compared to SAVR, but lower risk of repeat aortic intervention (SHR 0.33).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: